Drug intelligence / Profile preview

pembrolizumab + toripalimab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This is a combination of two PD-1 inhibitors: pembrolizumab (Keytruda) and toripalimab (Loqtorzi). Both are humanized monoclonal antibodies that target the PD-1 receptor but bind to different epitopes. Toripalimab has demonstrated 12-fold higher binding affinity to PD-1 compared to pembrolizumab and shows more potent T cell activation in preclinical studies. This combination is not a standard therapeutic regimen but is being investigated in comparative clinical trials.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on pembrolizumab + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + toripalimab.

Explore the full profile